JP4625800B2 - マリノブファゲニンの増加を利用して子癇前症の有無を判定する方法及び関連装置 - Google Patents

マリノブファゲニンの増加を利用して子癇前症の有無を判定する方法及び関連装置 Download PDF

Info

Publication number
JP4625800B2
JP4625800B2 JP2006503224A JP2006503224A JP4625800B2 JP 4625800 B2 JP4625800 B2 JP 4625800B2 JP 2006503224 A JP2006503224 A JP 2006503224A JP 2006503224 A JP2006503224 A JP 2006503224A JP 4625800 B2 JP4625800 B2 JP 4625800B2
Authority
JP
Japan
Prior art keywords
marinobufagenin
eclampsia
patient
increase
hypertension
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2006503224A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006517670A (ja
JP2006517670A5 (enExample
Inventor
ビー． プシェット，ジュールズ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tulane University
Original Assignee
Tulane University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tulane University filed Critical Tulane University
Publication of JP2006517670A publication Critical patent/JP2006517670A/ja
Publication of JP2006517670A5 publication Critical patent/JP2006517670A5/ja
Application granted granted Critical
Publication of JP4625800B2 publication Critical patent/JP4625800B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5302—Apparatus specially adapted for immunological test procedures
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9453—Cardioregulators, e.g. antihypotensives, antiarrhythmics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2006503224A 2003-02-04 2004-02-02 マリノブファゲニンの増加を利用して子癇前症の有無を判定する方法及び関連装置 Expired - Fee Related JP4625800B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44473003P 2003-02-04 2003-02-04
PCT/US2004/002802 WO2004071273A2 (en) 2003-02-04 2004-02-02 Method of employing elevation of marinobufagenin in determining the presence of preeclampsia and related apparatus

Publications (3)

Publication Number Publication Date
JP2006517670A JP2006517670A (ja) 2006-07-27
JP2006517670A5 JP2006517670A5 (enExample) 2007-04-05
JP4625800B2 true JP4625800B2 (ja) 2011-02-02

Family

ID=32869296

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006503224A Expired - Fee Related JP4625800B2 (ja) 2003-02-04 2004-02-02 マリノブファゲニンの増加を利用して子癇前症の有無を判定する方法及び関連装置

Country Status (7)

Country Link
US (1) US7439071B2 (enExample)
EP (1) EP1592967A4 (enExample)
JP (1) JP4625800B2 (enExample)
AU (1) AU2004210650C1 (enExample)
BR (1) BRPI0407213A (enExample)
CA (1) CA2515012A1 (enExample)
WO (1) WO2004071273A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7402313B2 (en) 2002-07-25 2008-07-22 Charles David Adair Method for controlling preeclampsia and eclampsia
US7794716B2 (en) 2002-07-25 2010-09-14 Glenveigh Pharmaceuticals, Llc Antibody composition and passive immunization against pregnancy-induced hypertension
ATE537823T1 (de) * 2004-10-19 2012-01-15 Univ Tulane Verfahren zur behandlung von präeklampsie beim menschen mit resibufagenin
US8038997B2 (en) 2005-06-27 2011-10-18 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Anti-marinobufagenin antibodies and methods for their use
US20070257366A1 (en) * 2006-05-03 2007-11-08 Taiwan Semiconductor Manufacturing Company, Ltd. Barrier layer for semiconductor interconnect structure
US20080299602A1 (en) * 2007-05-31 2008-12-04 Puschett Jules B Methods of Employing Vascular Leakage to Diagnose a Capillary Leak Disorder
WO2010104646A1 (en) * 2009-03-09 2010-09-16 Scott and White Memorial Hospital Method of testing a patient for hypertension and related method of treatment and test kit
US20110008904A1 (en) * 2009-07-10 2011-01-13 Scott And White Memorial Hospital And Scott, Sherwood, And Brindley Foundation Method for determining if a patient has a traumatic brain injury and related apparatus
US20110207154A1 (en) * 2010-01-12 2011-08-25 Scott & White Healthcare Method for determination of marinobufagenin levels and compounds employable in such method
US20160299130A1 (en) * 2015-04-09 2016-10-13 Jules B. Puschett Telocinobufagin (TCINO) in the Diagnosis and Pathogenesis of Preeclampsia, Traumatic Brain Injury and Acute Respiratory Distress Syndrome
EP3813879A1 (en) * 2018-06-21 2021-05-05 CTS Biopharma LLC Anti-marinobufagenin antibodies and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5079171A (en) * 1988-09-15 1992-01-07 Adeza Biomedical Corporation Determining pregnancy induced hypertension and eclampsia by immunoassay of cellular fibronectin
EP0440750A4 (en) * 1988-12-14 1991-10-09 The Regents Of The University Of California Diagnostic assay for the detection of preeclampsia
GB9213934D0 (en) * 1992-06-30 1992-08-12 Smithkline Beecham Corp Chemical compounds
US5770376A (en) 1992-12-02 1998-06-23 Biomedical Sciences Research Laboratories, Inc. Method of diagnosing and treating myocardial infarction and hypertension
WO1994012210A1 (en) 1992-12-02 1994-06-09 Bagrov Alexei Y Anti-edlf antibody, composition thereof and method of diagnosing and treating cardiac arrhythmias, hypertension
US5543138A (en) * 1994-03-10 1996-08-06 Genetics Institute, Inc. Methods of diagnosing and treating preeclampsia
GB9618931D0 (en) * 1996-09-11 1996-10-23 Univ London Inositol phosphoglycans for therapeutic use in pre-eclampsia and diabetes
US20030044856A1 (en) 1997-09-26 2003-03-06 Puschett Jules B. Method of determining volume dependent hypertension through protein reduction in phosphorylation or concentration and related apparatus
JPH11271222A (ja) * 1998-03-24 1999-10-05 Sekisui Chem Co Ltd 尿検査方法
US7794716B2 (en) * 2002-07-25 2010-09-14 Glenveigh Pharmaceuticals, Llc Antibody composition and passive immunization against pregnancy-induced hypertension
US10167609B1 (en) 2018-01-12 2019-01-01 Cashman Dredging & Marine Contracting Co., LLC Carouseling articulated dredge and barge

Also Published As

Publication number Publication date
AU2004210650A1 (en) 2004-08-26
EP1592967A4 (en) 2007-06-20
BRPI0407213A (pt) 2006-02-07
US20060263891A1 (en) 2006-11-23
JP2006517670A (ja) 2006-07-27
WO2004071273A2 (en) 2004-08-26
AU2004210650B2 (en) 2009-07-30
AU2004210650C1 (en) 2010-01-14
EP1592967A2 (en) 2005-11-09
WO2004071273A3 (en) 2005-02-03
CA2515012A1 (en) 2004-08-26
US7439071B2 (en) 2008-10-21

Similar Documents

Publication Publication Date Title
Anderson et al. Biochemical markers to predict preeclampsia
Powers et al. Maternal serum soluble fms-like tyrosine kinase 1 concentrations are not increased in early pregnancy and decrease more slowly postpartum in women who develop preeclampsia
Vaisbuch et al. Circulating angiogenic and antiangiogenic factors in women with eclampsia
Kim et al. The relationship of the level of circulating antiangiogenic factors to the clinical manifestations of preeclampsia
Huppertz Biology of preeclampsia: Combined actions of angiogenic factors, their receptors and placental proteins
Seki The role of the renin–angiotensin system in the pathogenesis of preeclampsia–new insights into the renin–angiotensin system in preeclampsia
Niromanesh et al. Association of hypertriglyceridaemia with pre-eclampsia, preterm birth, gestational diabetes and uterine artery pulsatility index
JP4625800B2 (ja) マリノブファゲニンの増加を利用して子癇前症の有無を判定する方法及び関連装置
Triunfo et al. Association of first-trimester angiogenic factors with placental histological findings in late-onset preeclampsia
Kurtoglu et al. Role of vascular endothelial growth factor and placental growth factor expression on placenta structure in pre‐eclamptic pregnancy
Atakul Serum levels of angiogenic factors distinguish between women with preeclampsia and normotensive pregnant women but not severity of preeclampsia in an obstetric center in Turkey
McMaster-Fay Pre-eclampsia–a disease of oxidative stress resulting from the catabolism of DNA (primarily fetal) to uric acid by xanthine oxidase in the maternal liver: A hypothesis
Yelikar et al. Association of maternal serum homocysteine level with severity of preeclampsia: A case control study
US8080539B2 (en) Method of treating human preeclampsia employing resibufagenin
Gerszi et al. Evaluation of oxidative/nitrative stress and uterine artery pulsatility index in early pregnancy
CN112180098B (zh) 胎盘相关疾病标志物的筛选方法及标志物
Huppertz et al. First trimester serum markers to predict preeclampsia
Hamed et al. Evaluation of changes in renal function of pregnant women with preeclampsia in Al-jabal Al-akhdar
Fitriana et al. Evaluation of placental bed uterine in L-NAME-induced early-onset preeclampsia (EO-PE) like the rat model
Kurmanova et al. Dynamics of serum cytokines in preeclampsia
Oun et al. Comparative study of mean platelet volume in preeclampsia versus normal pregnancy in 3rd trimester
Nasser et al. Correlation between serum & urinary placental protein (Pp13) in pre-eclamptic women at their third trimester
WO2008150870A1 (en) Methods of employing vascular leakage to diagnose a capillary leak disorder
Ruiz et al. Biomarkers in Pre-eclampsia: Is it Possible to Predict it?
Luchian et al. New Various Histopathological Findings of the Placenta in Preeclampsia

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070131

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070131

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20091007

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091020

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100115

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100720

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100915

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20101012

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20101108

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131112

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees